Among them, those named “dual-site” AChE inhibitors occupy a particularly prominent position for the treatment of AD since they can interact with both the CAS and the PAS of AChE, leading to the potent activation of the cholinergic system, as well as the efficient inhibition of AChE-promoted Aβ production and aggregation [12]. The gene discussed is ACHE; the disease is Alzheimer disease.